Guided Therapeutics bullish on cervical scan despite second FDA knock-back
This article was originally published in Clinica
Executive Summary
Guided Therapeutics’ share price has plunged again after it was hit by a second FDA rejection of its flagship LuViva noninvasive cervical cancer scanning technology. Although a blow to the company, the agency’s not-approvable letter is potentially good news for the producers of rival cervical cancer screening techniques such as Pap smears and human papillomavirus (HPV) testing, including Hologic and Qiagen.